跳至主要内容
临床试验/EUCTR2018-003180-54-RO
EUCTR2018-003180-54-RO进行中(未招募)1 期

An extension study to evaluate the long-term outcomes of subjects who received treatment for retinopathy of prematurity in Study 20090 - FIREFLeYe Next

Bayer AG0 个研究点目标入组 102 人开始时间: 2022年3月18日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Bayer AG
入组人数
102

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects are eligible to be included in the study only if both of the following criteria apply:
  • 1.Subject was treated in Study 20090
  • 2.Age less than 13 months of chronological age
  • 3.Signed informed consent from parent(s)/legally authorized representative(s) as described in Section 10.1.3 of the clinical trial protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 102
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects are excluded from the study if the following criterion applies:
  • Medical Conditions
  • 1. Subject has a condition preventing participation in the study, or performance of study procedures

研究者

发起方
Bayer AG

相似试验